ReviewCurrent atherosclerosis reports2016
Discontinuation of Statins: What Are the Risks?
Review in Current atherosclerosis reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Statin liver safety in non-alcoholic fatty liver disease: A systematic review and metanalysis.British journal of clinical pharmacology · 2022Pooled it
- Coenzyme q10 liquid supplementation in dyslipidemic subjects with statin-related clinical symptoms: a double-blind, randomized, placebo-controlled study.Drug design, development and therapy · 2019Trial
- Non-Alcoholic Steatohepatitis Patient Characterization and Real-World Management Approaches in Italy.Pragmatic and observational research · 2024Article
- Deprescribing in Palliative Cancer Care.Life (Basel, Switzerland) · 2022Review
- Sex-Differences in Discontinuation of Statin Treatment in Cancer Patients the Year before Death.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Article
- Comparative effect of nutraceuticals on lipid profile: a protocol for systematic review and network meta-analysis.BMJ open · 2020Article
- Effect of statins on the association between high temperature and all-cause mortality in a socioeconomically disadvantaged population: a cohort study.Scientific reports · 2019Article
- New insights into ANGPLT3 in controlling lipoprotein metabolism and risk of cardiovascular diseases.Lipids in health and disease · 2018Review
- Should Patients Continue to Receive Statins Once They Reach 80 Years of Age?The Canadian journal of hospital pharmacyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The key benefits of statin therapy have been well established in both primary and secondary prevention cardiovascular patients. Many studies have shown a significant statin discontinuation rate within the first year of initiation whether for primary or secondary prevention. National guidelines for the management of dyslipidemia highlight the lack of benefit seen with statin therapy in patients with chronic kidney disease receiving dialysis, heart failure with reduced ejection fraction, and patients greater than 75 years of age without atherosclerotic cardiovascular disease. Available data outside of these patient populations do not support discontinuation of statin therapy. Recent studies support an association with statin discontinuation and increased risk of myocardial infarction and cardiovascular death. Based on the available data, discontinuation of statin therapy should be carefully considered.
Indexed as
Identifiers
27221503What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.